Aker BioMarine ASA (OSL:AKBM)

Q2 2026 Aker Biomarine ASA Earnings Call Transcript

Jul 10, 2026 / 07:00 AM GMT

Release Date Price: kr97.3 (-2.70%)

Transcript

Key Points

Positve

Aker BioMarine ASA (STU:1PG) reported a 5% year-over-year increase in revenue, reaching $57 million for the second quarter of 2026.
Juven Health Ingredient segment achieved a record quarter with revenues of $34.1 million, up 17% from the previous year.
The Creole Oil business experienced a strong growth of 21% year-over-year, driven by solid volume growth and favorable pricing.
A new contract with Lusoveta is expected to generate $4 million in the first year and $6 million in the second year, indicating future revenue growth.
The company secured a significant new Superba business, which is anticipated to be one of the largest customers, starting in the fourth quarter of 2026.

Negative

Consumer Health Products segment reported a weak quarter with revenues down 6% year-over-year.
Adjusted EBITDA decreased by 4% to $12.9 million compared to the same quarter last year.
Production issues in Houston, including power outages, led to lower production and sales of QHP products.
Net financial items were higher than normal due to redemption costs associated with bond refinancing.
Net loss for the quarter was $5.4 million, partly due to non-recurring project costs and restructuring expenses.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AKBM.OL - Aker Biomarine ASA
Q2 2026 Aker Biomarine ASA Earnings Call
Jul 10, 2026 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, and welcome to the presentation of the second quarter 2026 for Aker B-Marine. Where myself, Mats Janssen, the CEO and the CFO, Katrina Klavnas, will take you through the financials and the highlights from the quarter.

The second quarter of '26 was yet another strong quarter for Akademarium, delivering $57 million of revenue, up 5% year-over-year for the group as a whole, with an adjusted EBITDA of $12.9 million for the quarter.

Juven Health Ingredient delivered another record quarter with revenues at $34.1 million, that's up 17% from the same quarter last year, with an adjusted EBITDA of $15.9 million, up 14% year-over-year.

The underlying Creole Oil business grew 21% year-over-year, continuing

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.